Indian Pharmaceutical Industry is Going Places

Posted by:

India is one of the most cost-effective pharmaceutical markets in the world.

It is a matter of time, before markets realize that India could compete with the local manufacturers of every country, and in fact beat them at it.

At Dorphyll Healthcare, we have successfully multiplied our business, supplied drugs to all corners of South India and we are expanding rapidly not just in India but also all over the world.

Exporters have generated a lot of interest in our company (get ...

Continue Reading →
0

SCHEDULE H1 Is Finally Here!

Posted by:

H1 is very important, as it assists in curbing resistance of patients to higher antibiotics.

It would however hamper the prospect of smaller manufacturers, since the retailers wouldn’t be interested in maintaining the records of so many products.

Over the years, we have seen that the schedules have not been properly implemented. Hence, instead of coming out with new schedules, government should come up with a strategy to implement the existing schedules effectively. This will definitely help the entire industry in planning ...

Continue Reading →
0

FDA BAN of Manufacturing facilities in India

Posted by:

It’s a sad feeling for all of us.

In the past two years, Indian manufacturing facilities have faced a lot of flak for not conforming to the safety standards set by the drug authorities of importing countries.

This led to mistrust and decreased business for Indian manufacturers, who are otherwise at-par with the world standard (in terms of quality).

Hence manufacturing facilities are taking corrective action, and will be better than most drug manufacturers of the world. It is a steep learning curve, ...

Continue Reading →
0

IS DPCO Really That effective?

Posted by:

DPCO (Drug Price Control Order) has been updated once again. This time, as pointed in Times Of India, the issues have not been addressed satisfactorily.

Though the intention is right, the implementation is not. A few products have price control for one dosage form, whereas no price control for the other dosage forms.

This would lead to unfair practices. If you were to put a dosage of 1gm under price control, and 500mg out of it, then the patient would be prescribed ...

Continue Reading →
0